Galapagos Scipher Medicine, Galapagos Sign IBD Drug Development Deal The companies will jointly validate novel drug targets identified by Scipher's molecular interaction network platform for patients with inflammatory bowel disease. Charles River Laboratories Buying BioFocus, Argenta from Galapagos for up to $187M NEW YORK (GenomeWeb News) – Charles River Laboratories has signed a definitive agreement to purchase Galapagos' BioFocus and Argenta service division operations for a total consideration of €134 million ($187 million), the companies announced today. In Brief This Week: AB Sciex; Enzo Biochem; Sigma-Aldrich; Precision BioSciences, Cellectis; Quidel; Galapagos, AstraZeneca; Cartagenia Galapagos' BioFocus Business Extends Contract with Amgen The extension calls for the use of BioFocus' target discovery platform to deliver novel targets in support of Amgen's therapeutic programs. BioFocus Joins Argenta, Genentech Research Alliance BioFocus will provide Genentech with integrated medicinal chemistry, in vitro biology, and ADME services. Jul 12, 2010 NIH Extends Agreement with Galapagos for MLSMR Jun 28, 2010 Galapagos Raises $430K through Warrants Exercise Feb 2, 2010 Galapagos Acquires Drug Discovery Services Business Jan 20, 2010 EMBL Launches Genomic-Based Drug Data Resource Oct 16, 2009 Galapagos Raises $27.1M in Share Placement Oct 14, 2009 Galapagos Expands Merck Drug Target Pact Jul 22, 2009 StarDrop Developers Acquire Software from BioFocus DPI, Launch New Firm Premium Mar 6, 2009 News Scan : Mar 6, 2009 Premium Mar 6, 2009 BioFocus' 2008 Revenues Increase 16 Percent Breaking News Sequencing Study Uncovers MERS-Related Coronavirus in Swiss Bats Angstrom Bio Raises $3M in Private Financing Eagle Biosciences, Genetic Analysis Ink Distribution Agreement for Gut Microbiota Test Centogene Q1 Revenues Grow More Than Fivefold Driven by COVID-19 Testing Epizyme Partnering With Quest Diagnostics for Lymphoma Mutation Testing Enzo Biochem, CLX Health Partner to Support COVID-19 Testing for International Travel The Scan CDC Calls Delta "Variant of Concern" CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern." From FDA to Venture Capital Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post. Consent Questions Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles. Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.